Design and Preliminary Clinical Studies of an MRI-Guided Transrectal Prostate Intervention System


1Johns Hopkins University, Baltimore, Maryland, United States, 2NCI - NIH-DHHS, Bethesda, Maryland, United States, 3Roswell Park Cancer Institute, Buffalo, United States, 4Princess Margaret Hospital, Toronto, Canada, 5Queen's University, Kingston, Canada

Introduction and Objective

This paper reports on the development and preliminary clinical studies of a new system for MRI guided transrectal prostate interventions. This system employs a novel hybrid tracking method which (a) reduces procedure time and (b) simplifies deployment on different scanners while achieving the needle placement accuracy of more complex previously reported methods, e.g. [1,2]. Transrectal MRI guided prostate interventions such as biopsies and gold marker placements inside a high-field MR scanner have been reported in initial clinical trials, utilizing active [1,2] and passive fiducial tracking [3]. MRI provides superior soft-tissue contrast and has the potential to improve image-guided prostate interventions presently performed with ultrasound [4].

Materials and Methods

Figure 1 shows the interventional device placed in a standard prostate phantom (CIRS Inc, Norfolk, VA). The device guides the needle tip of a standard automatic MR compatible biopsy gun (Invivo Germany GmbH, Schwerin, Germany) to a predetermined target in the prostate. The device contains an endorectal probe with integrated single loop imaging coil. A two channel surface imaging coil is placed underneath the phantom to enhance the MRI signal. A steerable needle channel is integrated into the probe. The three degrees of freedom (DOF) to reach a target in the prostate are rotation of the probe, angulation change of the steerable needle channel, and insertion of the needle.

The interventional device incorporates a hybrid tracking method comprised of passive fiducial marker tracking and joint encoders. At the beginning of the procedure, the initial position of the interventional device is obtained from MR images by segmenting fiducial markers placed on the device. Motion along the degrees of freedom of the interventional device from the initial position, is redundantly encoded by mechanical scales and MR compatible fiber optic joint encoders.

The interventional device employs two gadolinium fiducial marker tubes (Beekley Corp., Bristol, CT) incorporated into the main axis of the device and two marker tubes placed in line with the needle channel. A thin slab of 1x1x1mm isotropic, sagittal, proton density (PD) weighted TSE images in the plane of the markers is obtained. The software re-formats the sagittal images as axial images along the main axis of the interventional device and along the needle axis. In these re-formatted axial images the tubular markers appear as circles, allowing for precise automatic segmentation of the fiducial markers. The targeting accuracy of three biopsy needle placements was assessed using proton weighted axial TSE needle confirmation images (Figure 2, second row). The void created by the susceptibility artifact of the biopsy needle is visible close to the target. The mean in-plane targeting error for the biopsies was 1.1 mm with a maximum error of 1.8 mm. No needle confirmation image was taken from target number 3. The gold marker location for target number 1 was confirmed on subsequent needle placement images (Figure 2, third row). The distance from the center of the marker to the target location was 1.1 mm.

The pathology report revealed that the biopsy sample taken at target number 1, was positive for prostate cancer. One biopsy was procured from each of three target sites, while one target was biopsied twice. A gold marker was implanted at each target location after biopsy of the site.

Results

Two clinical procedures have been performed on a 3T Philips Intera MRI scanner (Philips Medical Systems, Best, NL). One procedure encompassed combined biopsy and gold marker placements, the second employed biopsy only.

Figure 4 shows the results of the combined procedure. Four targets were selected on axial TSE T2-weighted images (Figure 2, top row). The targets were placed at hypo-intense regions on the T2 weighted images, which represent suspicious areas for prostate cancer. One biopsy was procured from each of three target sites, while one target was biopsied twice. A gold marker was implanted at each target location after biopsy of the site.

The targeting accuracy of three biopsy needle placements was assessed using proton weighted axial TSE needle confirmation images (Figure 2, second row). The void created by the susceptibility artifact of the biopsy needle is visible close to the target. The mean in-plane targeting error for the biopsies was 1.1 mm with a maximum error of 1.8 mm. No needle confirmation image was taken from target number 3. The gold marker location for target number 1 was confirmed on subsequent needle confirmation images (Figure 2, third row). The distance from the center of the marker to the target location was 1.1 mm.

The pathology report revealed that the biopsy sample taken at target number 1, was positive for prostate cancer with a Gleason grade of 3+4. The patient was subsequently treated with external radiation beam therapy. The implanted gold markers were used to adjust for daily set-up changes to optimize the radiation therapy. The average procedure time was 75 minutes.

Conclusion

We reported the results of initial clinical procedures to evaluate the feasibility of performing prostate interventions with the proposed system. The clinical procedures demonstrated accurate and fast needle targeting of the complete clinical target volume. The errors and procedure time compare favorably to reported results (average error 1.8 mm and average procedure times of 76 minutes) achieved with a previously reported active tracking method in clinical trials [1,2]. The hybrid tracking method allows this system to be used on any MRI scanner without extensive systems integration and calibration.

References